Light Chain Bioscience

Executive Summary

Light Chain Bioscience (LCB) is a clinical-stage Swiss biotechnology company pioneering native bispecific antibody therapeutics through its proprietary Kλ body platform. The platform enables the creation of multispecific antibodies with enhanced safety and efficacy, targeting immuno-oncology pathways such as CD47 and CD28. LCB's lead programs aim to address critical limitations in cancer immunotherapy, including tumor resistance and immune evasion. The company's differentiated approach leverages the natural pairing of lambda light chains to generate bispecific antibodies with favorable pharmacokinetics and reduced toxicity compared to conventional formats. With a focus on first-in-class and best-in-class candidates, LCB is positioned to capture significant value in the rapidly evolving bispecific antibody market, which is projected to exceed $20 billion by 2028.

Upcoming Catalysts (preview)

• Q4 2026Phase 1/2 interim data readout for lead CD47xPD-L1 bispecific antibody35% success
• Q2 2027Potential strategic partnership or licensing deal for Kλ body platform40% success
• Q1 2027IND filing for CD28 bispecific candidate in solid tumors50% success